Oral altretamine used as salvage therapy in recurrent ovarian cancer.

Abstract

BACKGROUND:

Altretamine has reported efficacy in the treatment of recurrent ovarian cancer following platinum-based therapy. This report presents the cases of two long-term survivors with recurrent ovarian cancer given oral altretamine.

CASES:

Two patients diagnosed with stage IIIC ovarian cancer underwent optimal cytoreductive surgery. Both women were subsequently treated with platinum-based chemotherapy. One had persistent cancer documented 2 months post therapy, while the other was disease-free for 22 months before recurring. Both received altretamine in a salvage setting. Each of these women achieved a prolonged response to third-line altretamine therapy, and one of whom was disease-free for 4 years and the other remains disease-free over 7 years following initiation of salvage therapy.

CONCLUSION:

Outpatient-administered oral altretamine can provide a prolonged disease-free interval with minimal toxicity.

• Authors: John K Chan, Vera Loizzi, Alberto Manetta, Michael L Berman
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 92 Issue 1 Pg. 368-71 (Jan 2004) ISSN: 0090-8258 [Print] United States
• PMID: 14751188 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Altretamine

Topics

• Administration, Oral
• Aged
• Altretamine (administration & dosage)
• Antineoplastic Agents, Alkylating (administration & dosage)
• Female
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Ovarian Neoplasms (drug therapy)
• Salvage Therapy